Moussab Damlaj

1.1k total citations
65 papers, 625 citations indexed

About

Moussab Damlaj is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Moussab Damlaj has authored 65 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 23 papers in Genetics and 19 papers in Oncology. Recurrent topics in Moussab Damlaj's work include Hematopoietic Stem Cell Transplantation (14 papers), Acute Myeloid Leukemia Research (13 papers) and Lymphoma Diagnosis and Treatment (13 papers). Moussab Damlaj is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Acute Myeloid Leukemia Research (13 papers) and Lymphoma Diagnosis and Treatment (13 papers). Moussab Damlaj collaborates with scholars based in Saudi Arabia, United States and Canada. Moussab Damlaj's co-authors include Shahrukh K. Hashmi, Mark R. Litzow, Mohsen Alzahrani, William J. Hogan, Mrinal M. Patnaik, Riad El Fakih, Muhammad Riaz, Tarek Kashour, Bader Alahmari and Imad M. Tleyjeh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Moussab Damlaj

55 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Moussab Damlaj Saudi Arabia 13 193 190 136 112 101 65 625
Mehmet Ali Erkurt Türkiye 15 224 1.2× 207 1.1× 183 1.3× 107 1.0× 64 0.6× 94 731
Changcheng Zheng China 14 290 1.5× 340 1.8× 168 1.2× 74 0.7× 73 0.7× 65 743
Ioannis Mantzaris United States 12 182 0.9× 248 1.3× 363 2.7× 94 0.8× 134 1.3× 70 812
Seth J. Rotz United States 15 229 1.2× 70 0.4× 192 1.4× 88 0.8× 52 0.5× 62 664
Tulio E. Rodriguez United States 14 214 1.1× 147 0.8× 223 1.6× 41 0.4× 80 0.8× 53 724
Valérie Coiteux France 16 351 1.8× 142 0.7× 244 1.8× 182 1.6× 290 2.9× 55 836
Lalita Norasetthada Thailand 11 240 1.2× 110 0.6× 137 1.0× 169 1.5× 64 0.6× 105 595
Andy Peniket United Kingdom 16 390 2.0× 59 0.3× 303 2.2× 123 1.1× 89 0.9× 40 791
Judith Brody United States 13 219 1.1× 66 0.3× 193 1.4× 201 1.8× 109 1.1× 45 778
John Doyle Canada 14 352 1.8× 80 0.4× 147 1.1× 81 0.7× 95 0.9× 27 698

Countries citing papers authored by Moussab Damlaj

Since Specialization
Citations

This map shows the geographic impact of Moussab Damlaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moussab Damlaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moussab Damlaj more than expected).

Fields of papers citing papers by Moussab Damlaj

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moussab Damlaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moussab Damlaj. The network helps show where Moussab Damlaj may publish in the future.

Co-authorship network of co-authors of Moussab Damlaj

This figure shows the co-authorship network connecting the top 25 collaborators of Moussab Damlaj. A scholar is included among the top collaborators of Moussab Damlaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moussab Damlaj. Moussab Damlaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shafqat, Areez, et al.. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers. 15(18). 4550–4550. 19 indexed citations
3.
Masuadi, Emad, et al.. (2021). Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study. Critical Care Research and Practice. 2021. 1–11. 9 indexed citations
4.
Damlaj, Moussab, et al.. (2021). Voluntary blood donation among female health care university students in Saudi Arabia, knowledge and status. SHILAP Revista de lepidopterología. 10(6). 2353–2357. 7 indexed citations
5.
Abuelgasim, Khadega A., et al.. (2021). Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience. SHILAP Revista de lepidopterología. 15. 100240–100240. 5 indexed citations
6.
Khalid, Farhan, Moussab Damlaj, Mohsen Alzahrani, Khadega A. Abuelgasim, & Giamal Gmati. (2020). Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis. Hematology/Oncology and Stem Cell Therapy. 14(3). 252–256. 12 indexed citations
7.
Tleyjeh, Imad M., Zakariya Kashour, Moussab Damlaj, et al.. (2020). Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clinical Microbiology and Infection. 27(2). 215–227. 127 indexed citations
8.
Damlaj, Moussab, Farhan Khalid, Bader Alahmari, et al.. (2020). Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. Current Research in Translational Medicine. 68(3). 131–137. 5 indexed citations
9.
Jazieh, Abdul Rahman, Mohsen Alzahrani, Ahmed Alaskar, et al.. (2020). Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. Clinical Lymphoma Myeloma & Leukemia. 21(1). e66–e75. 20 indexed citations
10.
Damlaj, Moussab, et al.. (2019). Systemic mastocytosis with renal light chain amyloidosis: associated non-mast cell disorder or concurrent disease. Journal of Hematopathology. 12(3). 157–162.
11.
Damlaj, Moussab, et al.. (2019). Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e559–e563. 8 indexed citations
12.
Damlaj, Moussab, Riad El Fakih, & Shahrukh K. Hashmi. (2018). Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care. Blood Reviews. 33. 63–73. 40 indexed citations
13.
Damlaj, Moussab, et al.. (2018). Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma. World Journal of Transplantation. 8(7). 252–261. 3 indexed citations
14.
15.
Alzahrani, Mohsen, Ahmed Alaskar, Moussab Damlaj, et al.. (2017). Non-Myeloablative Transplant in Severe Sickle Cell Disease Is Safe & Effective. Single Center Experience from Saudi Arabia. Blood. 130. 5549–5549. 1 indexed citations
16.
Damlaj, Moussab, et al.. (2017). Lymphocyte recovery is an independent predictor of relapse in allogeneic hematopoietic cell transplantation recipients for acute leukemia. World Journal of Transplantation. 7(4). 235–235. 2 indexed citations
17.
18.
19.
Damlaj, Moussab & Chantal Séguin. (2014). Refractory autoimmune hemolytic anemia in a patient with DiGeorge syndrome treated successfully with plasma exchange: a case report and review of the literature. International Journal of Hematology. 100(5). 494–497. 9 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mehmet Ali Erkurt Breakdown of academic impact, for papers by Changcheng Zheng Breakdown of academic impact, for papers by Ioannis Mantzaris Breakdown of academic impact, for papers by Seth J. Rotz Breakdown of academic impact, for papers by Tulio E. Rodriguez Breakdown of academic impact, for papers by Valérie Coiteux Breakdown of academic impact, for papers by Lalita Norasetthada Breakdown of academic impact, for papers by Andy Peniket Breakdown of academic impact, for papers by Judith Brody Breakdown of academic impact, for papers by John Doyle
Rankless by CCL
2026